The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.

ABSTRACT: Interstitial lung diseases (ILD) encompasses a heterogeneous group of parenchymal lung diseases characterized by variable amounts of inflammation and fibrosis. The targeting of fibroblasts and myofibroblasts with antifibrotic treatments is a potential therapeutic target for these potentially fatal diseases. Treprostinil is unique among the prostacyclin mimetics in that it has distinct actions at additional prostaglandin receptors. Preclinical and clinical evidence suggests that treprostinil has antifibrotic effects through the activation of the prostaglandin E receptor 2 (EP₂), the prostaglandin D receptor 1 (DP₁), and peroxisome proliferator-activated receptors (PPAR). In vivo studies of EP₂ and the DP₁ have found that administration of treprost

SUBMITTER: Kolb M 

PROVIDER: S-EPMC9402520 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature